DNA Repair Gene Associated with Clinical Outcome of Epithelial Ovarian Cancer Treated with Platinum-based Chemotherapy

Kang, Shan; Sun, Hai-Yan; Zhou, Rong-Miao; Wang, Na; Hu, Pei; Li, Yan

추천

검색

자료유형: 학술저널

저자정보: Kang, Shan (Department of Obstetrics and Gynaecology, Hebei Medical University, Fourth Hospital) Sun, Hai-Yan (Department of Obstetrics and Gynaecology, Hebei Medical University, Fourth Hospital) Zhou, Rong-Miao (Department of Molecular Biology, Hebei Medical University, Fourth Hospital) Wang, Na (Department of Molecular Biology, Hebei Medical University, Fourth Hospital) Hu, Pei (Department of Obstetrics and Gynaecology, Hebei Medical University, Fourth Hospital) Li, Yan (Department of Molecular Biology, Hebei Medical University, Fourth Hospital)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제14권 제2호

발행연도: 2013.1

수록면: 941 - 946 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Objective: The nucleotide excision repair (NER) and base excision repair (BER) pathways, two DNA repair pathways, are related to platinum resistance in cancer treatment. In this paper, we studied the association between single nucleotide polymorphisms (SNPs) of involved genes and response to platinum-based chemotherapy in epithelial ovarian cancer. Method: Eight SNPs in XRCC1 (BER), XPC and XPD (NER) were assessed in 213 patients with epithelial ovarian cancer using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and primer-introduced restriction analysis-polymerase chain reaction (PIRA-PCR) techniques. Results: The median progression-free survival (PFS) of patients carrying the Lys/Lys and Lys/Gln+Gln/Gln genotype of the XPC Lys/Gln polymorphism were 25 and 12 months, respectively (P=0.039); and the mean overall survival (OS) of patients was 31.1 and 27.8 months, respectively (P=0.048). Cox's multivariate analysis suggested that patients with epithelial ovarian cancer with the Gln allele had an increased risk of death (HR=1.75; 95% CI=1.06-2.91) compared to those with the Lys/Lys genotype. There are no associations between the XPC PAT+/-, XRCC1 Arg194Trp, Arg280His, Arg399Gln, and XPD Asp312Asn, Lys751Gln polymorphisms and the survival of patients with epithelial ovarian cancer when treated with platinum-based chemotherapy. Conclusion: Our results indicated that the XPC Lys939Gln polymorphism may correlate with clinical outcome of patients with epithelial ovarian cancer when treated with platinum-based chemotherapy in Northern China.

#DNA repair gene #polymorphisms #epithelial ovarian cancer #platinum-based chemotherapy

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요